• Scope and Methodology
• Size and Growth of the Market
• Trends Affecting the Market
• Market Outlook

Chapter Two: Introduction and Overview

• History of Women’s Health
• Female Reproductive System
• Hormone Regulation
• Demographics
• Epidemiology
  • Autoimmune Disease
  • Cancer
  • Gynecological Infection and Sexually Transmitted Disease
  • Hormone-Related Indications
  • Osteoporosis
  • Urinary Bladder Disorders
  • Lifestyle Patterns

Chapter Three: Autoimmune Diseases

• Overview
• Chronic Fatigue Syndrome
• Treatment
• Fibromyalgia
• Treatment
• Rheumatoid Arthritis
• Treatment
• Scleroderma
• Treatment
• Sjogren’s Syndrome
• Treatment
• Systemic Lupus Erythematosus
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • 406381
  • Anergix RA
  • Ampligen
  • Actemra
  • Apilmod
  • Arcoxia
  • CDP 870
  • CTLA 41G
  • Denosumab
  • Interleukin (IL-1)
  • LymphoStat-B
  • MabThera
  • Milnacipran
  • Prestara
  • Prexige
  • Prograf
  • Org 39141
  • Riquent
  • Veldona
  
  
• Competitive Market

Chapter Four: Cancer

• Overview
• Breast Cancer
  • Overview
  • Treatment
  
  
• Cervical Cancer
  • Overview
  • Treatment
  
  
• Endometrial Cancer
  • Overview
  • Treatment
  
  
• Ovarian Cancer
  • Overview
  • Treatment
  
  
• Vaginal Cancer
  • Overview
  • Treatment
  
  
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Advexin
  • Arzoxifene
  • Atamestane
  • Avastin
  • BrevaRex
  • Cervarix
  • Combidex
  • Edotecarin
  • Evista
  • Herceptin
  • Ixabepilone
  • Lapatinib
  • Lasofoxifene
  • MDX-010
  • Myocet
  • OvaRex
  • Pemtumomab
  • Tavocept
  • Taxoprexin
  • Telcyta
  • Temsirolimus
  • Tykerb
  • Vinorelbine IV
  • Xinlay
  • XRP 98
  • Xytotax
  • Yondelis
  
  
• Competitive Market

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

• Overview
• AIDS
  • Overview
  • Treatment
  • Agenerase
  • Aptivus
  • Combivir
  • Crixivan
  • Entriva
  • Fortovase
  • Fuzeon
  • Hivid
  • Invirase
  • Kaletra
  • Kivexa
  • Lexiva
  • Prezista
  • Rescriptor
  • Reyataz
  • Sustiva
  • Trizivir
  • Truvada
  • Viracept
  • Viramune
  
  
• Bacterial Vaginosis
  • Overview
  • Treatment
  
  
• Cervical Dysplasia
  • Overview
  • Treatment
  
  
• Chlamydia
  • Overview
  • Treatment
  
  
• Condyloma Acuminata
  • Overview
  • Treatment
  • Aldara
  • Alferon N Injection
  • Condylox
  • Gardasil
  
  
• Genital Herpes
  • Overview
  • Treatment
  • Zovirax
  
  
• Gonorrhea
  • Overview
  • Treatment
  
  
• Hepatitis
  • Overview
  • Treatment
  • Baraclude
  
  
• Pelvic Inflammatory Disease
  • Overview
  • Treatment
  
  
• Syphilis
  • Overview
  • Treatment
  
  
• Toxic Shock Syndrome
  • Overview
  • Treatment
  
  
• Yeast Infections
  • Overview
  
  
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Ampligen
  • Aplaviroc
  • BufferGel
  • Carraguard
  • Clevudine
  • HepeX-B
  • Hyphanox
  • IFN-alpha Lozenge
  • Interferon Alfacon/Ribaviron Combination
  • Maraviroc
  • Multiferon
  • PRO 2000
  • Proleukin
  • Resiquimod
  • SAVVY
  • Simplirix
  • SPO1A
  • Telbivudine
  • Ushercell
  • Zadaxin
  • Competitive Market

Chapter Six: Hormone-Related Disorders

• Overview
• Contraception
  • Overview
  • Treatment
  • Oral Contraceptives
  • Depo-Provera
  • Birth Control Patch
  • Vaginal Ring
  • Emergency Contraception and Early Option
  • Implant
  • Intrauterine Device (IUD)
  
  
• Endometriosis
  • Overview
  • Treatment
  
  
• Fibroids
  • Overview
  • Treatment
  
  
• Infertility
  • Overview
  • Treatment
  
  
• Menopause
  • Overview
  • Treatment
  
  
• Menstrual Disorders
  • Amenorrhea
  • Dysmenorrhea
  
  
• Sexual Dysfunction
  • Overview
  • Treatment
  
  
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Alista
  • Alprox-TD
  • Asoprisnil
  • Bijuva
  • Bio-E-Gel
  • BufferGel
  • E2/DNG Pill
  • Evamist
  • FC Patch
  • Femprox Cream
  • Intrinsa
  • LibiGel
  • IoGen
  • Lybrel
  • Menopausal Levonorgestrel System
  • NOMAC/E2
  • Preven Emergency Contraceptive Kit
  • Tanaproget
  • Tostrelle
  
  
• Competitive Market

Chapter Seven: Osteoporosis

• Overview
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Aclasta
  • AMG 162
  • ALX 1-11
  • Arzoxifene
  • Banzedoxifene
  • Denosumab
  • Lasofoxifene (Oporia)
  • Livial
  • Oral Calcitonin
  • Ostarine
  • Preos
  • S12911
  
  
• Competitive Market

Chapter Eight: Urinary Bladder Disorders

• Overview
• Cystitis
  • Overview
  • Treatment
  
  
• Incontinence
  • Overview
  • Treatment
  • Overactive Bladder
  • Treatment
  • Alternative Treatments
  
  
• Interstitial Cystitis
  • Overview
  • Treatment
  
  
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Competitive Market

Chapter Nine: Issues and Trends

• Women’s Health Initiative
• Perimenopausal Use of Contraceptives
• Fosamax Patents Void in European Market
• Insurance Coverage for Contraceptives
• Oral Contraceptives in Japan
• Ovarian Cancer Test
• New Pap Test Screening Guidelines
• Estrogen Labeling
• Osteoporosis Drug Opportunities in Asia
• OTC Plan B
• Cervical Cancer Vaccines
• Women’s Access to Health Care and Insurance
• Issues of Middle-Aged and Older Women
• Possible AIDS Vaccine

Chapter Ten: World Market Summary

• Overview
• Total Market Size and Forecast
• Market Analysis

Chapter Eleven: Competitor Profiles

• Industry Structure and Participants
• Akzo Nobel nv Organon International
• Amgen, Inc.
• AstraZeneca PLC
• Barr Laboratories, Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Company, Inc.
• Novartis International AG
• Pfizer, Inc.
• Procter & Gamble Company
• Roche
• Sanofi -Aventis
• Schering AG
• Serono International S.A.
• Wyeth

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: Market Summary: The Worldwide Market for Prescription Drugs for Women’s Healthcare 2000-2010
• Figure 1-1: The Market for Women’s Healthcare Trending in Revenues by Segment 2000-2010

Chapter Two: Introduction and Overview

• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2005
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2005 (Difference, in Years, between Females and Males)
• Table 2-2: World Population Growth: Total World Population and Selected Country or Regions by Sex, 2000-2025
• Figure 2-2: World Population Growth by Sex 2000-2025
• Figure 2-3: United States Population Growth by Sex 2000-2025
• Figure 2-4: Five Major European Countries* Population Growth by Sex 2000-2025
• Figure 2-5: Japan Population Growth by Sex 2000-2025
• Table 2-3: World Female Population Growth by Selected Country/Region and Age Group, 2000-2025
• Figure 2-6: World Female Population Growth by Selected Age Group 2000-2025
• Figure 2-7: United States Female Population Growth by Selected Age Group 2000-2025
• Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000-2025
• Figure 2-9: Japan Female Population Growth by Selected Age Group 2000-2025
• Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type (Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis, Scleroderma, Sjogren’s Disease, Systemic Lupus Erythematosus) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
• Table 2-5: Estimated Incidence and Mortality of Female Cancers by Type (Breast, Cervical, Endometrial, Ovarian) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
• Table 2-6: Estimated Female Incidence/Prevalence of Gynecological and Sexually Transmitted Diseases by Type ((AIDS/HIV, Bacterial Vaginosis, Cervical Dysplasia, Chlamydia, Genital Herpes, Gonorrhea, Human Papilloma Virus, Hepatitis [Sexually Transmitted], Pelvic Inflammatory Disease, Syphilis, Toxic Shock Syndrome, Yeast Infection) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
• Table 2-7: Gynecological and Sexually Transmitted Diseases Diagnostic Testing Procedure Volume by Type (Pap, Pelvic Exams, HIV Tests, Other STD Tests, Mammograms), Five-Year Average 2000-2005
• Table 2-8: Estimated World and U.S. Female Incidence/Prevalence of Hormone-Related Indications by Type (Contraception, Endometriosis, Fibroids, Infertility, Menopause), Five-Year Average 2000-2005
• Table 2-9: Estimated World and U.S. Contraceptive Use by Method ((Female Sterilization, Oral Pill, Implant, Injectable, IUD, Diaphragm, Female Condom, Other Methods), Five-Year Average 2000-2005
• Table 2-10: Estimated Female Prevalence of Osteoporosis by Type (Diagnosed, Low-Bone Mass [At Risk], Osteoporosis-related Fractures) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
• Table 2-11: Estimated Female Incidence/Prevalence of Urinary Bladder Disorders by Type (UTI, Incontinence, Overactive Bladder, Interstitial Cystititis) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
• Table 2-12: Estimated Female Statistics Concerning Lifestyle Patterns Contributing to Disease by Type of Behavior and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005

Chapter Three: Autoimmune Diseases

• Table 3-1: The World Market for Autoimmune Disease Drugs for Women by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2000-2010
• Figure 3-1: The World Market for Autoimmune Disease Drugs for Women Revenues by Type 2000-2010
• Figure 3-2: The World Market for Autoimmune Disease Drugs for Women Share by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2005 & 2010
• Table 3-2: The World Market for Autoimmune Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 3-3: The World Market for Autoimmune Disease Drugs for Women Share by Geographic Region 2005 and 2010
• Table 3-4: The World Market for Autoimmune Disease Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Four: Cancer

• Table 4-1: The World Market for Cancer Drugs for Women by Type (Anti-metabolites, Alkylating Agents, Hormone Therapy, Biologic Therapies) 2000-2010
• Figure 4-1: The World Market for Cancer Drugs for Women Revenues by Type 2000-2010
• Figure 4-2: The World Market for Cancer Drugs for Women Share by Type 2005 and 2010
• Table 4-2: The World Market for Cancer Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 4-3: The World Market for Cancer Drugs for Women Share Percentage 2005 and 2010
• Table 4-3: Products in Development for Women’s Cancers (Product, Indication, Developer, Phase) 2005
• Table 4-4: The World Market for Cancer Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2005

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

• Table 5-1: Currently Available HIV Pharmaceuticals
• Table 5-2: Currently Marketed Bacterial Vaginosis Pharmaceuticals
• Table 5-3: Currently Marketed Chlamydia Pharmaceuticals
• Table 5-4: Currently Marketed Condyloma Treatments
• Table 5-5: Currently Marketed Herpes Virus Treatments
• Table 5-6: Currently Marketed Hepatitis Treatments
• Table 5-7: Currently Marketed PID Treatments
• Table 5-8: Currently Marketed Prescription Yeast Infection Treatments
• Table 5-9: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women by Type (Antibacterials, Antifungals, Antivirals) 2000-2010
• Figure 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Type 2000-2010
• Figure 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Type 2005 and 2010
• Table 5-10: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographic Region 2005 and 2010
• Table 5-11: Products in Development for Women’s Gynecological Infections and Sexually Transmitted Diseases (Product, Indication, Developer, Phase)
• Table 5-12: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Six: Hormone-Related Disorders

• Table 6-1: Selected Oral Contraceptives Available 2005
• Table 6-2: Selected Hormone Replacement Therapies
• Table 6-3: The World Market for Hormone-Related Disorder Drugs for Women by Type (Contraceptives, Infertility Agents, Hormone Replacents, Other Hormone Therapies) 2000-2010
• Figure 6-1: The World Market for Hormone-Related Disorder Drugs for Women by Type 2000-2010
• Figure 6-2: The World Market for Hormone-related Disorder Drugs for Women Share by Type 2005 and 2010
• Table 6-4: The World Market for Hormone-Related Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 6-3: The World Market for Hormone-Related Disorder Drugs for Women Share by Geographic Region 2005 and 2010
• Table 6-5: Hormonal Preparations in Research and Development for Women (Product, Indication, Developer, Phase)
• Table 6-6: The World Market for Hormone-Related Disorder Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 6-4: The World Market for Hormone-Related Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Seven: Osteoporosis

• Table 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type (Bone Metabolism Regulators, Hormones/SERMs) 2000-2010
• Figure 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type 2000-2010
• Figure 7-2: The World Market for Osteoporosis Drugs for Women Share by Type 2005 and 2010
• Table 7-2: The World Market for Osteoporosis Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2005 and 2010 Table 7-3: Products in Development for Osteoporosis (Product, Developer, Phase)
• Table 7-4: The World Market for Osteoporosis Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 7-4: The World Market for Osteoporosis Drugs for Women Market Share by Leading Supplier 2005

Chapter Eight: Urinary Bladder Disorders

• Table 8-1: Medications That Can Affect Urination
• Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type (Antibiotics, Anticholinergics/Antispasmodics, Cholinergics, Other) 2000-2010
• Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 2000-2010
• Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2005 and 2010
• Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
• Figure 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographic Region 2005 and 2010
• Table 8-4: Products in Development for Urinary Disorders (Product, Indication, Developer, Phase)
• Table 8-5: The World Market for Urinary Bladder Disorder Drugs for Women Revenues and Market Share by Supplier 2005
• Figure 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Ten: World Market Summary

• Table 10-1: The Worldwide Market for Prescription Drugs in Women’s Health, Revenues by Segment (Autoimmune, Cancer, Gynecologic Infections and STDs, Hormones, Osteoporosis, Urinary Bladder Disorders), 2000-2010
• Figure 10-1: The Market for Women’s Healthcare Revenues by Segment 2000-2010
• Figure 10-2: The Market for Women’s Healthcare Market Share by Type 2005 and 2010
• Table 10-2: Women’s Health Revenues and Segments of Participation by Leading Market Participants 2005